Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression

Read full text Summarise with VIRAT
Authors: Takashi Shimizu, Ryotaro Ohkuma, Mayumi Homma, Shingo Nakayama, Yosuke Sasaki, Satoshi Muto, Katsuaki Ieguchi, Makoto Watanabe, Akashi Taguchi, Daisuke Takayanagi, Youichiro Wada, Atsushi Horiike
+13 more Yutaro Kubota, Hirotsugu Ariizumi, Masahiro Shimokawa, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Emiko Mura, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Hiroyuki Suzuki, Toshiko Yamochi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for non-small-cell lung cancer (NSCLC), but predictive biomarkers for response remain limited. Quantification of Programmed Cell Death Ligand 1 (PD-L1) expression using a phosphor-integrated dot (PID) score has been shown to predict ICI efficacy in NSCLC and other cancers (1). However, PD-L1 expression is not always a reliable predictor, particularly in patients with low PD-L1 levels, highlighting the need for alternative biomarkers.Akkermansia muciniphila (Akk) plays multiple roles and has beneficial effects on systemic metabolism, immunity, the intestinal barrier, and tumor progression (2)(3)(4). A Study has shown that intestinal Akk is overrepresented in cancer patients with progression-free survival (PFS) of more than 3 months or in ICI responders (4). A recent cohort study also demonstrated that intestinal Akk was associated with ICI efficacy in NSCLC patients, particularly in those with low PD-L1 expression (2). Furthermore, in a lung cancer animal model, it was observed that intestinal Akk could enter the bloodstream and subsequently colonize lung cancer tissue (5).Based on these findings, we hypothesized that tumor-associated Akk may be related to prognosis or ICI efficacy in NSCLC patients, independent of PD-L1 expression. In this study, we investigated the clinical significance of tumor Akk expression as assessed by immunohistochemistry (IHC) in NSCLC patients treated with ICIs.Material and methodsThis study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Ethics Committees of Showa Medical University School of Medicine (approval number: 2772) and Fukushima Medical University (approval number: 2019-262). Informed consent was obtained from all patients involved in the study.This study enrolled 60 NSCLC patients with metastatic or recurrent cancer who were treated with ICIs. It was a multicenter retrospective cohort study, and patients were diagnosed and treated at Showa Medical University Hospital and Fukushima Medical University Hospital from December 2015 to December 2022. All patients received treatment regimens, including ICIs as shown in Table 1, which were administered according to clinical practice.Each patient's treatment response was evaluated using computed tomography scans for imaging assessments. Treatment efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 (6). Overall survival (OS) was defined as the time from the start of the first administration of treatment to the date of death from any cause or the last follow-up. Progression-free survival (PFS) was defined as the time from the start of treatment to the first documented instance of disease progression, death from any cause, or the last follow-up, whichever occurred first. The cut-off date for follow-up was set as December 2022.The "median PFS" and "median OS" from phase III pivotal clinical trials were used to uniformly evaluate the treatment efficacy of patient populations. The patients were divided into two groups (responders and non-responders) based on their treatment response. We then performed an analysis to compare Akk and PD-L1 expression in each group.All tumor tissue specimens used to evaluate Akk expression were obtained before each patient received ICI treatment. The immunohistochemistry (IHC) staining procedure using DAB, and the method of evaluating Akk expression, were performed according to standard clinical protocols. 60 Formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained by biopsy or resection were prepared for analysis. FFPE cut to a thickness of 4 μm were deparaffinized and stained using an automated immuno-stainer BOND-III (Leica Biosystems, Germany) using the manufacturer's IHC protocol. Antigen retrieval was performed using the BOND Enzyme Pretreatment Kit (Leica Biosystems, AR9551) at 37°C for 10 min, followed by incubation with Akkermansia muciniphila primary antibody (1:500, Sigma-Aldrich, SAB4200870, Germany) at room temperature for 15 min. DAB detection was performed using the BOND Polymer Refine Detection (Leica Biosystems, DS9800). Three independent pathologists independently evaluated all 60 immuno-stained slides. We defined Akk positivity as clear intracellular staining of Akk in multiple fields of view. Appropriate positive controls were included in each IHC run. The same tumor tissue specimens were used to evaluate PD-L1 expression. The method for PD-L1 PID scoring was conducted as previously reported (1).We also performed immunofluorescence staining of CD3 and CD68 on specimens with low PD-L1 expression (n=30). We sliced 4-μm sections from paraffin blocks and placed them on glass slides, which were then deparaffinized and rehydrated. ). An All-in-One Fluorescence Microscope (BZ-X810, KEYENCE, OSAKA, Japan) was used to assess the positivity according to double immunostaining, as previously reported (7).Total RNA from tumor tissues was isolated by RNeasy Micro kit (Qiagen, Netherlands). The RNA integrity score was calculated with the TapeStation High Sensitivity RNA Kit (Agilent, CA, USA) in a 2200 TapeStation (Agilent, CA, USA). RNA-Seq libraries were prepared with the SMART-Seq® Stranded Kit (# 634444, Takara Bio, Japan). The libraries were sequenced on the NovaSeq 6000 system (Illumina) as paired-end 150 base reads.RNA libraries were sequenced on an Illumina NovaSeq 6000 platform, generating 2 × 150 bp pairedend reads. Read alignment was performed using STAR (version 2.7.10a) with default parameters, mapping to the human genome (GRCh38) and transcriptome (GENCODE version 40) as reference datasets. Gene expression levels were quantified as fragments per kilobase of exon per million reads mapped (FPKM) using StringTie (version 2.2.1).To visualize the effects of Akk positivity on FPKM expression levels between Akk positive and Akk negative in all specimens (n=6 per group), PD-L1 low specimens (n=3 per group) and PD-L1 high specimens (n=3 per group).For RNA-sequencing data in all specimens, PD-L1 low specimens and PD-L1 high specimens, gene annotation enrichment analysis was performed for KEGG pathway analysis, using the functional annotation tool in DAVID Bioinformatics Resources 2021 (https://davidbioinformatics.nih.gov/home.jsp).Statistical analyses were performed, and figures were generated using GraphPad Prism 8.4.3 software (GraphPad Software Inc., San Diego, CA, USA) or JMP software (SAS institute., NC, USA). Spearman's correlation coefficient was used to analyze the associations between variables. Un-paired t test was used to compare values between two groups. Statistical significance was defined as a p-value

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis Lung Cancer Research Studies

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1827736–1827736
Publication date
26 March 2026
Language
EN